Advertisement

Topics

PREDICT: Nutrigenetic Profile of Patients With Weight Loss Success

2016-09-22 21:08:21 | BioPortfolio

Summary

This observational study will investigate the potential clinical utility of the Pathway Fit® test by investigating whether patients who successfully lose weight (defined as losing at least 5% of body weight 8 weeks after initiation) in the MOVE! or TeleMOVE! Weight Management programs have a distinct nutrigenetic profile over those that were unable to lose a significant amount of weight. We will use electronic records to identify all individuals who have successfully completed the MOVE! program (i.e. attended the full 8 week course) or TeleMOVE! program. In addition we will find age- and gender- matched individuals who attended and completed the MOVE! or TeleMOVE! programs but did not lose weight. After completion of the MOVE! or TeleMOVE! programs Veterans will submit a saliva sample for the Pathway Fit® test. Also, blood will be collected for storage for further studies on metabolomics. The start and end weight of all participants will be recorded. The nutrigenic profiles of those with successful weight loss will be compared to those less successful to determine if this cohort has a particular genetic profile.

Description

The overall prevalence of metabolic syndrome in the general US population is estimated to be 22-34.5% with greater prevalence in certain populations (e.g. Mexican and African Americans, women). These numbers have been consistent with the rise of prevalence of obesity in the US population to 34.9%, which has remained stable over the last 10 years. Veterans are particularly predisposed to metabolic syndrome since the prevalence of obesity is much higher among their ranks. Since the annual medical cost of those who are obese or have metabolic syndrome is $1429 higher than those at a healthy weight, the impact on the cost of healthcare for Veterans can be potentially tremendous. This is mainly since obesity is strongly associated with many chronic diseases, including type 2 diabetes, cardiovascular disease, some types of cancer (endometrial, postmenopausal breast, kidney, and colon), musculoskeletal disorders, sleep apnea, and gallbladder disease.

In order to combat the obesity epidemic in Veterans, the U.S. Department of Veterans Affairs created the MOVE! Weight Management Program (MOVE!) in 2006. MOVE! is an evidence-based weight-management program designed for patients followed in primary care clinics and who have a BMI of ≥30kg/m2 or with a BMI of ≥25kg/m2 with 1 or more obesity-related conditions (e.g. diabetes, hypertension, dyslipidemia). The efficacy of the program is measured by the % of patients who losing at least 5% of body weight at 8 weeks and 6 months after first session. In addition, TeleMOVE! is a program recently initiated within the VA system to help individuals who cannot make it to the VA MOVE! program due to their work schedule or distance from VA clinic.

This observational study will investigate the potential clinical utility of the Pathway Fit® test by investigating whether patients who successfully lose weight (defined as losing at least 5% of body weight 8 weeks after initiation) in the MOVE! or TeleMOVE! programs have a distinct nutrigenetic profile over those that were unable to lose a significant amount of weight. We will use electronic records to identify all individuals who have successfully completed the MOVE! program (i.e. attended the full 8 week course) or TeleMOVE! program. In addition we will find age- and gender- matched individuals who attended and completed the MOVE! Or TeleMOVE! programs but did not lose weight. After completion of the MOVE! Or TeleMOVE! programs Veterans will submit a saliva sample for the Pathway Fit® test. The start and end weight of all participants will be recorded. The nutrigenic profiles of those with successful weight loss will be compared to those less successful to determine if this cohort has a particular genetic profile. Also, blood will be collected for storage for further studies on metabolomics.

To encourage participation, participants will be reimbursed for their participation in the study and the Pathway Fit® test results will be provided to all. Comparisons on all pertinent measures will be made between those achieving at least 5% weight loss and those that did not.

Upon completion of the study, the clinical utility of the Pathway Fit® test can be further investigated to determine if the successful nutrigenic profile can predict clinical outcomes of the participants in the MOVE! program or other lifestyle management programs.

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Conditions

Obesity

Intervention

Pathway Genomics FIT test

Status

Enrolling by invitation

Source

San Diego Veterans Healthcare System

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-09-22T21:08:21-0400

Clinical Trials [691 Associated Clinical Trials listed on BioPortfolio]

The Study of Inflammation on Blood Glucose Levels in Obese People

Chronic subaccute inflammation may underlie the development of diabetes cardiovascular disease and other components of the metabolic syndrome. Rodent studies suggest diet induced obesity ...

Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease

Pathway Genomics Corporation (Pathway Genomics), a San Diego, California company, is involved in the development and validation of new molecular diagnostic assays for the analysis of circu...

Sleep Deprivation and Energy Balance

Observational and epidemiological studies have found a link between obesity and short sleep duration with the prevalence of both increasing in the past decades. At this time, it is unknow...

Compliance of Clinical Pathways in Elective Laparoscopic Cholecystectomy: Evaluation of Different Implementation Methods

Compliance to the clinical pathway, postoperative complication and total cost of the hospitalisation of patients undergoing elective cholecystectomy for symptomatic cholecystolithiasis wer...

PD-1/PD-L1 Pathway Study on Septic Patients

The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

PubMed Articles [14783 Associated PubMed Articles listed on BioPortfolio]

Types of Obesity and Its Association with the Clustering of Cardiovascular Disease Risk Factors in Jilin Province of China.

Cardiovascular disease (CVD) has become a serious public health problem in recent years in China. Aggregation of CVD risk factors in one individual increases the risk of CVD and the risk increases sub...

Soy Isoflavones Regulate Lipid Metabolism through an AKT/mTORC1 Pathway in Diet-Induced Obesity (DIO) Male Rats.

The pandemic tendency of obesity and its strong association with serious co-morbidities have elicited interest in the underlying mechanisms of these pathologies. Lipid homeostasis, closely involved in...

Attenuation of obesity-induced insulin resistance in mice with heterozygous deletion of ROCK2.

Obesity-associated insulin resistance is a major risk factor for the development of type 2 diabetes, cardiovascular disease and non-alcoholic liver disease. Over-activation of the RhoA-Rho kinase (ROC...

Swimming intervention mitigates HFD-induced obesity of rats through PGC-1α-irisin pathway.

Irisin, a newly discovered myokine, can drive the browning of white adipocytes to control body weight or mitigate obesity progression through regulating energy metabolism. However, the underlying mech...

Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women.

Positive energy imbalance and growth factors linked to obesity promote the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (mTOR) pathway. As the obesity-breast cancer associations dif...

Medical and Biotech [MESH] Definitions

The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.

A condition of having excess fat in the abdomen. Abdominal obesity is typically defined as waist circumferences of 40 inches or more in men and 35 inches or more in women. Abdominal obesity raises the risk of developing disorders, such as diabetes, hypertension and METABOLIC SYNDROME X.

A projective test used to evaluate a broad range of personality variables including pathology of thought and perception. The subject's responses to inkblot prints are scored along with subjective interpretation by the test administrator.

The systematic study of the complete DNA sequences (GENOME) of organisms.

A test to determine the lowest sound intensity level at which fifty percent or more of the spondaic test words (words of two syllables having equal stress) are repeated correctly.

More From BioPortfolio on "PREDICT: Nutrigenetic Profile of Patients With Weight Loss Success"

Quick Search
Advertisement
 

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Searches Linking to this Trial